---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-006991"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:13:00.449555+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Amylyx selects GLP-1 antagonist AMX0318 as development candidate for post-bariatric hypoglycemia

## Summary
- AMX0318 is a long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases.
- Candidate identified through research collaboration with Gubra; Gubra eligible for >$50M in development and commercial milestones.
- Handover of candidate triggers $4M milestone payment to Gubra; mid-single digit royalties on worldwide net sales.
- Amylyx expects to initiate IND-enabling studies and file an IND for AMX0318, though no specific timeline was provided.

## SEC filing metadata
- accession: 0001193125-26-006991
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000119312526006991/0001193125-26-006991-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000119312526006991/d45370d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-006991
- JSON: https://secwatch.observer/filing/0001193125-26-006991.json
- Plain text: https://secwatch.observer/filing/0001193125-26-006991.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.